Arcturus announces collaboration with csl to develop and commercialize self-amplifying mrna vaccines

San diego--(business wire)--arcturus therapeutics holdings inc. (the “company”, “arcturus”, nasdaq: arct), a leading clinical-stage messenger rna medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced a strategic collaboration with csl seqirus, a global vaccine leader, for the research, development, manufacture, and global commercialization of vaccines.
ARCT Ratings Summary
ARCT Quant Ranking